FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
FDA Guidance on CT Mgmt during COVID-19
U.S. Food & Drug Administration Health Care, Pharma Industry, Strategic PlanningRelated Articles
-
21 September 2020 2020 Virtual Conference: Pre...
-
4 June 2020 Leadership Lessons for Re-En...
-
18 April 2017 Value-Based Healthcare
-
18 April 2017 The Innovator's Prescription
Copyright © 1988 - 2019 Global Clinical Supplies Group (GCSG)